Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Haffner

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
NPJ Precision Oncology|May 17, 2024
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlatesAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Molecular Cancer Research : MCR|January 27, 2026
OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundanceMatthew J Bernard, Andrea Gallardo, Angel Ruiz, et al.
The Journal of Pathology|October 18, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancerRadhika A Patel, Erolcan Sayar, Ilsa Coleman, et al.
JCO Precision Oncology|October 5, 2020
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate CancerDavid R Wise, Jeffrey A Schneider, Joshua Armenia, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Signal Transduction and Targeted Therapy|July 25, 2024
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradationAlvaro Quintanal-Villalonga, Kenta Kawasaki, Esther Redin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate CancerAdam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancerA Mandl, S Jasmine, Teg Krueger, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2024
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapiesSamir Zaidi, Jooyoung Park, Joseph M Chan, et al.
Biorxiv : the Preprint Server for Biology|April 22, 2024
Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted TherapiesSamir Zaidi, Jooyoung Park, Joseph M Chan, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
NPJ Precision Oncology|May 17, 2024
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlatesAzra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Molecular Cancer Research : MCR|January 27, 2026
OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundanceMatthew J Bernard, Andrea Gallardo, Angel Ruiz, et al.
The Journal of Pathology|October 18, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancerRadhika A Patel, Erolcan Sayar, Ilsa Coleman, et al.
JCO Precision Oncology|October 5, 2020
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate CancerDavid R Wise, Jeffrey A Schneider, Joshua Armenia, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Signal Transduction and Targeted Therapy|July 25, 2024
CDC7 inhibition impairs neuroendocrine transformation in lung and prostate tumors through MYC degradationAlvaro Quintanal-Villalonga, Kenta Kawasaki, Esther Redin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2022
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate CancerAdam G Sowalsky, Ines Figueiredo, Rosina T Lis, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancerA Mandl, S Jasmine, Teg Krueger, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 5, 2024
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapiesSamir Zaidi, Jooyoung Park, Joseph M Chan, et al.
Biorxiv : the Preprint Server for Biology|April 22, 2024
Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted TherapiesSamir Zaidi, Jooyoung Park, Joseph M Chan, et al.
Pageof 21